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THE IMPACT OF PREMATURE DISCONTINUATION OF
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DISORDER
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USA; 3Duke University, Durham, NC, USA
OBJECTIVE: Antidepressant therapy is highly effective in
patients with major depressive disorder (MDD). Evidence has
shown that most patients stay on pharmacotherapy for less than
6 months even though clinical guidelines recommend treatment
for longer periods of time. The objective of this study was to
assess the impact of premature discontinuation of antidepressant
therapy on costs and outcomes in MDD patients. METHODS:
We created a simulation model to compare the costs and out-
comes associated with patients who respond to treatment with
a selective serotonin reuptake inhibitor (SSRI) and discontinue
treatment prematurely to those who respond to SSRIs and com-
plete the recommended course of treatment. Patients are outpa-
tients and are assumed to follow treatment as recommended by
the clinical guidelines except when early discontinuation occurs.
The model considers medication, primary care physician visit,
specialist (i.e., psychiatrist, hospital days, suicide, etc.), and
adverse event costs. Treatment efﬁcacy was taken from published
meta-analyses, and early discontinuation was estimated from the
published literature. Resource use was estimated from the clini-
cal guidelines and published literature. Unit costs were drawn
from standard published sources and inﬂated to 2003 dollars.
RESULTS: Over the course of 5 years, we observe that continu-
ation patients (i.e. patients who complete a recommended course
of treatment) have 155 fewer symptom days, 19 fewer disability
days, and lower costs by $2133 than discontinuation patients
(i.e. patients who discontinue early) when having relapses/recur-
rences. In the index episode, continuation patients incur more
costs than discontinuation patients due to increase usage of drugs
and physician. However, patients who discontinue incur more
costs later due to higher relapse/recurrence rates. CONCLU-
SION: By encouraging patients to complete a full course of drug
therapy, patients will incur fewer costs and fewer symptom and
disability days.
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USING PATIENT REPORTED OUTCOMES (PROS) TO
DETERMINE DEPRESSION AND ANXIETY POPULATIONS IN
FOUR COUNTRIES
Edmondson M, Mills D
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVES: To utilize international patient reported out-
comes (pros) data and identify the size and impact of patient
populations suffering from either anxiety or depression in four
countries: United States, Great Britain, Germany, and France.
METHODS: An annual, self-reported study of consumer atti-
tudes and behaviors conducted by consumer health sciences was
ﬁelded in June 2003. Over 53,000 adults, 18 years of age or
older, completed the survey in the U.S. (36,452), Great Britain
(5,071), France (5,082) and Germany (7,056). We stratiﬁed and
weighted the sample by key demographics. All respondents were
asked if they experienced anxiety or depression and if they had
their condition physician diagnosed. Included in the survey were
questions regarding hospitalization, worker productivity and the
sf-8. RESULTS: The number of anxiety or depression sufferers
in the U.S. is almost twice that of the number of anxiety or
depression sufferers in Great Britain, France, and Germany com-
bined. Thirty-six and nine-tenths percent of the U.S. adult 
population, 77.1 million people, sufferer from either anxiety or
depression while 40 million adults in France, Great Britain, and
Germany combined suffer from either anxiety or depression.
German sufferers of anxiety or depression reported the lowest
sf-physical health score among the four countries. French 
sufferers of anxiety or depression had the highest mean number
of days missed work among those who reported to have missed
work among the four countries. CONCLUSIONS: the percent
and size of the U.S. adult population suffering from anxiety or
depression far exceeds sufferers in Great Britain, France, and
Germany. Quality of life, hospitalization and worker productiv-
ity vary greatly within each country. Further research into the
reasons behind these differences will provide additional under-
standing into the nuances of each country’s mental health 
population.
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OBJECTIVE: To examine the frequency of relapse in a popula-
tion of Bipolar Disorder (BD) patients under conditions of
routine clinical practice. METHODS: Prospective data continues
to be collected at 14 Canadian centres for patients diagnosed
with BD, types I/II, who initially met the criteria for a mood
episode and required a change in treatment within 3-months
from the date of registration. Data includes medical/clinical
history with subsequent quarterly follow-up to determine relapse
frequency. The study commenced April 2002 and we report on
results to the end of November 2003. RESULTS: Of 193 ana-
lyzable patients, 124 (64%) were diagnosed with BD-I, and 69
(36%) with BD-II. Overall, the mood episode at baseline was
depressive in 38% (n = 74), manic in 19% (n = 37), other in 5%
and no episode in 37%. Of the depressed patients at baseline,
33 (46%) went on to have one or more additional episode of
depression and 11 (15%) had one or more episode of mania. Of
the baseline manic group, 17 (46%) experienced one or more
depressive episode and 7 (19%) had one or more additional
period of mania. Of the 72 patients with no mood episode at
baseline, 10% subsequently had two or less depressive episodes
and 6% had two or less manic periods. The total number of
relapses beyond the baseline mood episode, by study entry group
was: depressive (n = 73), manic (n = 38) and those with no
episode experienced a total of 11 relapses. The most frequently
prescribed medication for mood stabilization was Divalproex,
for depression Bupropion, and Olanzapine was the most 
frequently prescribed antipsychotic. CONCLUSIONS: Patients
entered into this study experiencing a mood episode were sig-
niﬁcantly more likely to endure additional relapses compared to
those patients enrolled free of such episodes. Relapse frequency,
in particular depressive relapse, remains high under current 
clinical practice.
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